7th Annual Cross Project Meeting of the IMI AMR Accelerator 2026 in Basel
5 March 2026, Basel
The IMI AMR Accelerator held its annual Cross Project Meeting on 5 March 2026 in Basel, hosted by BioVersys. The meeting was opened and chaired by Anders Karlén of Uppsala University and the agenda was dedicated to project updates and forward planning. Representatives from all eight projects — TRIC-TB, GNA NOW, ERA4TB, UNITE4TB, RespiriNTM, RespiriTB, PrIMAVeRa, and COMBINE — presented their latest results and outlined the work ahead. Lively and constructive discussions accompanied the presentations throughout, once again showcasing the vibrant and collaborative spirit of the Accelerator.
The afternoon was dedicated to the question of legacy. Josepine Fernow of Uppsala University (COMBINE) led an open workshop on sustaining the AMR Accelerator’s legacy, developing future-proof plans to ensure that scientific outputs, publications, and researchers of the Accelerator remain visible and accessible to the wider AMR community in the long term.
About the AMR Accelerator
The aim of the Antimicrobial Resistance (AMR) Accelerator Programme is to progress the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The programme comprises the following three pillars: a Capability Building Network, a Tuberculosis Drug Development Network, and the Portfolio Building Networks. The scope of the AMR Accelerator is broad; under one structure, it addresses many of the scientific challenges of AMR, and it supports the development of new ways to prevent and treat AMR. More broadly, the AMR Accelerator contributes to the European action plan on AMR. For more information on the AMR Accelerator, please visit https://www.amr-accelerator.eu/
About COMBINE
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853967. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies’ in kind contribution.
About the Innovative Medicine Initiative
About the Innovative Medicine Initiative The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. For more information on IMI, please visit https://www.imi.europa.eu/
Disclaimer
This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
